Media Resources


Measuring Medicine Prices, Availability, Affordability and Price Components (2nd Ed.)

Civil Society Urges Member States to Support the Dutch EU Presidency’s Vision on Access to Affordable Medicines

Assessing EU Funding for R&D for Poverty-related and Neglected Diseases

HAI Intervention at the United Nations High-Level Panel on Access to Medicines

Access to High-priced Medicines in Hospital Settings in Europe: A Study in Four European Countries

Study Finds Access to High-priced Medicines May Differ Across EU

Why You Should Be Concerned About TTIP and Access to Medicines

European CSOs Call for Rejection of EU Trade Secrets Directive


Trilogue Negotiations on Commission’s Proposal for Trade Secrets Directive

Medicines Transparency Alliance (MeTA) Evaluation

Global Snakebite Initiative Appoints Health Action International as Secretariat

Multi-sectoral NGO Coalition Calls on Parliament to Defend Safeguards for Consumers, Journalists, Whistleblowers, Public Authorities and Workers

Empty Gestures – The EU’s Commitments to Safeguard Access to Medicines

HAI and MSF Report Shows European Commission’s Access to Medicines Commitments are ‘Empty Gestures’

EU medicines policy & access to medicines

Early Access to Medicines Marketing Authorisation Flexibilities Should Only Respond to Unmet Medical Needs, Must Protect Patient Safety

Direct Patient Reporting in the EU: A Snapshot of Reporting Systems in Seven Member States

Declaration of Public Interest Regarding Access to Imatinib (Glivec) in Colombia

Health Action International Opposes European Parliament’s ISDS Compromise in TTIP

EU Medicines Policy and Access to Medicines

HAI Sexual Harassment Policy

Health Action International Launches New Brussels Office

Health Action International Criticises JURI Support for EU Trade Secrets Directive Report

How TTIP Could Damage Access to Affordable Medicines in the European Union

Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion

2014 Annual Report and Financial Statements

2014 Annual Report and Financial Statements

EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions


Retention of Medicines Policy in DG Health a Victory for Public Health Advocates

EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached